Ofir Moreno is a veteran biotech executive, with a passion for integrating advanced techniques and technologies towards the discovery and development of new drugs. Demonstrated success discovering novel small molecule drugs and targeted drug conjugates utilizing a variety of technological platforms and the application of model informed drugs. He held leading roles at MEI Pharma, Znomics, Dendreon, Amgen and Merck.

He brings more than 25 years of pharmaceutical R&D experience, spanning early drug discovery through clinical development. He is a veteran biotech executive, with a passion for integrating advanced techniques and technologies for the discovery and development of new drugs. His experience includes the discovery of novel drugs and prodrugs for oncology, CNS, and cardiovascular indications utilizing a variety of technological platforms, as well as the application of model-informed drug development for the advancement of drugs into first-in-human trials and onward to late-stage clinical trials.

Most recently, he was Senior Vice President of Pharmaceutical Sciences at MEI Pharma, where he was instrumental in establishing R&D operations, building MEI’s clinical pipeline, and partnering two drugs for late stage development and commercialization. Prior to MEI, he held positions of increasing responsibility in drug discovery at Merck, Amgen, Corvas International, and Dendreon. Dr. Moreno received his Ph.D. in Organic Chemistry from Harvard University under the guidance of Professor Yoshito Kishi, and a BA in Chemistry and Biology from Cornell University.